

<b>Nova Southeastern University – Institutional Review Board Standard Operating Policy and Procedures</b>		
<b>SOPP #1-1 Version #2</b>	<b>TITLE: IRB Jurisdiction and Authority</b>	
Date First Effective: December 14, 2017	Revision Date: August 10, 2023	Page 1 of 5

**OBJECTIVE**

To describe the policies and procedures relating to the Federal Wide Assurance for Nova Southeastern University and the Institutional Review Board’s (IRB) authority to review all research involving human participants to ensure it meets all regulatory requirements.

**GENERAL DESCRIPTION**

The IRB Office will maintain the university’s Federal Wide Assurance in good standing with the Office of Human Research Protections (OHRP) by submitting renewals and maintaining current roster information.

Federal regulations require that any institution requesting and receiving funds from a federal department or agency for research involving human participants must ensure that such research is reviewed and approved by the university’s IRB. In accordance with these federal regulations and institutional policies, the Nova Southeastern University (NSU) IRB has authority to review and approve all research involving human participants conducted by faculty, staff, or student investigators prior to implementation. The NSU IRB policy document entitled “Does my study need NSU IRB approval?” outlines activities that are considered human participants research or clinical investigation, requiring IRB review and approval.

**Definitions**

*Federal Wide Assurance (FWA):* This is documentation of an institution’s commitment to comply with Federal regulations and maintain policies and procedures for the protection of human participants. An institution must have an FWA in order to receive Department of Health and Human Services support for research involving human participants.

***Department of Health and Human Services (DHHS)/”Common Rule”***

*Clinical Trial:* A research study in which one or more human participants are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.

*Research (DHHS)<sup>1</sup>:* A systematic investigation, including research development, testing, and evaluation, designed to develop or contribute to generalizable knowledge. Activities that meet this definition are research, whether or not they are conducted or supported under a program that is considered research for other purposes. For example, some demonstration and service programs may include research activities.

<b>Nova Southeastern University – Institutional Review Board Standard Operating Policy and Procedures</b>		
<b>SOPP #1-1 Version #2</b>	<b>TITLE: IRB Jurisdiction and Authority</b>	
Date First Effective: December 14, 2017	Revision Date: August 10, 2023	Page 2 of 5

*Human participant (DHHS) <sup>2</sup>*: A living individual about whom an investigator conducting research (1) obtains information or biospecimens through intervention or interaction with the individual, and uses, studies, or analyzes the information or biospecimens; or (2) obtains or generates individually identifiable private information or identifiable biospecimens.

*Intervention*: Physical procedures by which information or biospecimens are gathered, or manipulations of the participant(s) environment are performed for research purposes.

*Interaction*: Communication or interpersonal contact between investigator and participant.

*Private information*: Information provided by an individual for specific purposes, and which the individual can reasonably expect will not be made public, or information about behavior that occurs in a context that the individual can reasonably expect that no observation or recording is taking place

*Identifiable Biospecimen*: A biospecimen for which the identity of the participant is or may readily be determined by the investigator or is associated with the biospecimen.

*Investigator (DHHS) <sup>2</sup>*: An individual performing various tasks related to the conduct of human subjects research activities, such as obtaining informed consent from subjects, interacting with subjects, and communicating with the IRB.

***Food and Drug Administration (FDA)***

*Investigator (FDA)*: An individual who actually conducts a clinical investigation (i.e., under whose immediate direction the drug is administered or dispensed to a subject). In the event an investigation is conducted by a team of individuals, the investigator is the responsible leader of the team.

*Clinical Investigation*: Involves the use of:

- a. A test article (i.e. drug, device, food substance, or biologic) **and**
- b. One or more human participants **and**
- c. Meets requirements for prior submission to the FDA (involves drugs or medical devices other than the use of FDA approved drugs or medical devices in the course of medical practice), **or** results are intended to be part of an application for research or a marketing permit.

If the activity involves the use of an FDA regulated test article (i.e., drug, device, food substance, or biologic under the purview of the FDA), the FDA definitions of “human participant” applies.

<b>Nova Southeastern University – Institutional Review Board Standard Operating Policy and Procedures</b>		
<b>SOPP #1-1 Version #2</b>	<b>TITLE: IRB Jurisdiction and Authority</b>	
Date First Effective: December 14, 2017	Revision Date: August 10, 2023	Page 3 of 5

*Research (FDA)*<sup>1</sup>: If research activity involves any of the following, FDA regulations 21 CFR 50 & 56 apply and require IRB approval prior to implementation.

- a. Any use of a drug in research other than the use of FDA approved drug in the course of medical practice;
- b. Any use of a medical device in studies where the purpose is to determine the safety or effectiveness of the device; or
- c. Data will be submitted to or held for inspection by the FDA as part of a marketing permit.

*Human participants (FDA Drug)*<sup>2</sup>: An individual who is or becomes a participant in research as either a recipient of a test article or as a control, or as an individual on whose specimen a device is used. A participant may be either a healthy individual or a patient [21 CFR 56.102€] (Drug, Food, Biologic).

*Human participants (FDA Device)*<sup>2</sup>: A human who participates in an investigation, either as an individual on whom or on whose specimen an investigational device is used, or as a control. A participant may be in normal health or may have a medical condition or disease [21 CFR 812.3(p)] (Medical Devices). This definition includes the use of tissue as specimens, even if they are unidentified.

<sup>1</sup>: Note, there are two (2) separate definitions for “Research” depending on whether DDHS or FDA regulations apply to the conduct of the research.

<sup>2</sup>: Note, there are three (3) separate definitions for “Human Participant” depending on whether DDHS or FDA regulations apply to the conduct of the research. Additionally, there is further breakdown of the definition of “Human Participant” in FDA regulations with regards to research involving a Device and Drug.

**RESPONSIBILITY**

Execution of SOPP: Principal Investigator (PI)/Research Personnel, Institutional Review Board (IRB) Office Staff, IRB Members, IRB Chairs

**PROCEDURES**

**A. Federal Wide Assurance**

- 1. The IRB Office will maintain the FWA by submitting requests for renewal and by submitting periodic updates of the IRB members and their alternates to OHRP.

<b>Nova Southeastern University – Institutional Review Board Standard Operating Policy and Procedures</b>		
<b>SOPP #1-1 Version #2</b>	<b>TITLE: IRB Jurisdiction and Authority</b>	
Date First Effective: December 14, 2017	Revision Date: August 10, 2023	Page 4 of 5

**B. IRB Authority to Review Human Participant Research**

1. It is the responsibility of each investigator to seek IRB review and approval prior to initiation of any research involving human participants or before conducting any clinical investigation. Investigators must submit the protocol for review and approval by the IRB.
2. If investigator believes their research does not fall under the jurisdiction of the IRB Office, they may file a “Human Subjects Research Determination xForm”. The IRB Office will determine if the activity meets the criteria for a “Not Human Subjects Research Determination” and will notify the investigator of its determination that this study does not require official IRB review and approval. The document entitled “Does my study need NSU IRB approval?” is available on the NSU IRB website and will guide the investigator in deciding whether to seek this determination.
3. The IRB only reviews HIPAA Authorizations as a part of the review of a protocol submission submitted for IRB review. Investigators whose research may include Protected Health Information are advised to review the HIPAA for Research Purposes policies created by the Office of Health Care Compliance that are available on the IRB website.
4. Investigators should contact their College Representative or IRB Office staff for advice on the applicability of the federal regulations and NSU policy.
5. The IRB Office has the sole responsible for communicating all decisions from the IRB or the Convened IRB to the investigator. These are communicated to the investigator via their official email (for NSU faculty, staff, and students) or professional email (for all non-NSU investigators).
6. The IRB has final authority on its determinations, including but not limited to decisions to defer a submission for more information, approval pending required modifications, and disapproval. No university official or committee may set aside or overrule a determination by the IRB.
7. IRB submissions are considered confidential information and will not be released by the IRB Office or any College Representative/Alternate Representative except as required by regulation. Dates of review and approval may be released by the IRB Office generally. The IRB Office will consider release of additional information on a case-by-case basis with receipt of a request that details the information requested, the reason(s) for the release of information by the IRB Office, and the proposed use of the information.

<b>Nova Southeastern University – Institutional Review Board Standard Operating Policy and Procedures</b>		
<b>SOPP #1-1 Version #2</b>	<b>TITLE: IRB Jurisdiction and Authority</b>	
Date First Effective: December 14, 2017	Revision Date: August 10, 2023	Page 5 of 5

8. Subject to generally-applicable principles of academic freedom, a university official administrator or committee may determine not to conduct research that has been approved by the IRB, including but not limited to the following reasons:
- a. A satisfactory contractual agreement could not be reached with a sponsor.
  - b. The research would require resources that the university could not provide.
  - c. The research would not be consistent with the university’s mission or values.
  - d. The research could expose the institution to unacceptable liability.

**REFERENCES**

21 CFR 56.102  
21 CFR 56.109(a)  
21 CFR 56.108(a)(1) and 56.109(f)  
21 CFR 56.108(a)(1), 56.109(a), 56.112, and 56.113  
21 CFR 812.3  
45 CFR 46.102  
45 CFR 46.103  
45 CFR 46.109(a)  
45 CFR 46.112  
45 CFR 46.115